Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aadipose-Derived Mesenchymal Stem Cells

Phase 1Cell therapy

TTaiwan Mitochondrion Applied Technology Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Parkinson's DiseaseNot yet recruiting

Idiopathic Parkinson's DiseasePhase 1

Not yet recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Idiopathic Parkinson's Disease

NCT05094011

Clinical

Trials by Indication[1]

Idiopathic Parkinson's Disease1 trial

Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease

Not yet recruiting·TTaiwan Mitochondrion Applied Technology Co., Ltd.·Phase 1·NCT05094011·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aadipose-Derived Mesenchymal Stem Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aadipose-Derived Mesenchymal Stem Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aadipose-Derived Mesenchymal Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiwan Mitochondrion Applied Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TTaiwan Mitochondrion Applied Technology Co., Ltd.

Related News